^
    Back
    Association details:
    Biomarker:FGFR2-BICC1 fusion
    Cancer:Cholangiocarcinoma
    Drug:Truseltiq (infigratinib) (FGFR inhibitor) +
    PD173074 (Tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Hepatology
    Title:

    Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma

    Excerpt:
    ...cholangiocarcinoma patients without KRAS/BRAF/ROS1 alterations and identified two fusion kinase genes, FGFR2-AHCYL1 and FGFR2-BICC1...Treatment with the fibroblast growth factor receptor (FGFR) kinase inhibitors BGJ398 and PD173074 effectively suppressed transformation.
    DOI:
    10.1002/hep.26890